The state of West Virginia has announced a partnership with GATC West Virginia, Inc., a subsidiary of GATC Health, to leverage GATC's transformative AI platform for drug discovery [a6dbe82e]. The West Virginia Economic Development Authority and West Virginia Jobs Investment Trust board of directors have approved a $5 million investment into GATC to expand their research and development lab in the West Virginia University Innovation Center. This investment will support the hiring of employees in their Morgantown lab and the completion of FDA application efforts for GATC's drug candidate for treating opioid use disorder. The collaboration between West Virginia and GATC underscores the state's commitment to fostering cutting-edge research and development in the healthcare and biotechnology sectors [a6dbe82e].
GATC's AI platform has demonstrated promising results in predicting the outcomes of pre-clinical laboratory experiments, including efficacy, safety, and off-target effects. A recent study conducted in collaboration with the University of California, Irvine, showed that GATC's AI platform significantly reduced the time and costs associated with preclinical trials. By combining AI-driven drug discovery with West Virginia's dedication to innovation, GATC aims to expedite the development of safer and more effective drugs, ultimately bringing them to market faster [a6dbe82e].